Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Mankind Pharma

Growth unavailable

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated unaudited results approved 26 Oct 2026; limited review

Reported revenue (₹ crore, except EPS in ₹): 4,337.86

Read summary and comparison caveats

Mankind Pharma reported consolidated September-quarter revenue from operations of ₹4,337.86 crore versus ₹3,697.16 crore a year earlier. Group profit after tax was ₹716.12 crore versus ₹520.18 crore; profit attributable to equity holders of the parent was ₹711.48 crore versus ₹511.51 crore. Basic EPS was ₹17.23 and diluted EPS ₹17.20.

  • The complete 30-page own-IR-linked filing was read, including standalone and consolidated statements, limited-review reports, notes, cash flows, proposed-amalgamation disclosures and separate debenture certificates. The consolidated statement on PDF page 16, cash flows on page 18, notes on page 19 and review report on pages 11-13 were visually checked. Source units are rupees crore, except EPS in rupees. Quarter columns are 30 Sep 2026 and 30 Sep 2025, not six-month columns.
  • The joint auditors give an unmodified consolidated limited-review conclusion dated 26 Oct 2026, with an Emphasis of Matter concerning uncertainty in income-tax proceedings after an earlier search. The appeals are pending for certain years. Note 4 reports aggregate assessment additions of ₹1,908.66 crore, not a stated cash-tax demand; certain disallowances of ₹369.44 crore were deleted on technical grounds, subject to the tax authorities' right to challenge. Management's view that remaining demands are not sustainable is its assessment, not a finding by Fistotex. A limited review is not an audit opinion.
  • The review report relies on other auditors or one of the joint auditors for specified subsidiaries, associates and joint ventures. Six subsidiaries used management-furnished unreviewed information, considered not material by management. Their quarter net loss included in the review scope was ₹3.44 crore. The auditors say their conclusion is not modified for those reliance matters.
  • Group profit after tax of ₹716.12 crore includes ₹711.48 crore attributable to parent equity holders and ₹4.64 crore to non-controlling interests. Total comprehensive income of ₹715.27 crore is a separate measure. The ₹3.68 crore share of associates' and joint ventures' net profit is added after income less expenses in reaching profit before tax. Standalone profit of ₹581.95 crore is a different basis and is not combined with consolidated figures.
  • The consolidated cash-flow statement covers six months, not the quarter: net cash inflow from operating activities was ₹1,818.50 crore versus ₹1,636.70 crore a year earlier. The BSV women's-health business common-control transfer affects standalone comparatives; consolidated note 6 explicitly says it does not affect these consolidated results. The prior full-year exceptional items are not current-quarter charges. The group reports one Pharmaceuticals segment.
  • The own-IR press release was also read in full as a cross-check. Its rounded revenue of ₹4,338 crore and PAT of ₹716 crore are not substituted for the statement's precise figures. No press-release EBITDA, market ranking, forecast, derived absolute from a percentage, calculated growth or unprinted sequential comparison is added here.
  • The separate debenture-covenant and asset-book-value reports on PDF pages 22-30 have restricted-purpose language. No certificate figure, certificate wording or certificate assurance is reproduced or relied on in this results entry. Those reports are kept distinct from the financial statements and independent financial-results review report.
  • Original factual summary with attribution and a primary-source link, not complete index coverage. Current own-IR footer, privacy policy, actual disclaimer-page DOM and retrieved documents were checked. The disclaimer page contains an email-specific notice, not an express sitewide public-summary licence or ban. No explicit sitewide restriction against short public factual summaries was located in those materials; this is not a reuse-licence claim. No investor-presentation copying, systematic exchange collection or investment recommendation.

Checked 18 Nov 2026

Open original filing
Read the complete published results desk